Drug intelligence / Profile preview

artemether + lumefantrine + amoxicillin

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral

Overview

A combination of three medications: artemether and lumefantrine (antimalarials) with amoxicillin (antibiotic). This combination may be used to treat concurrent malaria and bacterial infections, particularly in pediatric patients with malaria and pneumonia. Artemether-lumefantrine works against the erythrocytic stages of Plasmodium falciparum by inhibiting nucleic acid and protein synthesis, while amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.

Brand names: CoartemAmoxil
Other names: artemether + lumefantrine + amoxicillinZIMMAPS intervention

Targets

PBP (Penicillin-binding protein family)Heme

Beyond the preview

Go deeper on artemether + lumefantrine + amoxicillin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on artemether + lumefantrine + amoxicillin.

Explore the full profile